JP2021518348A5 - - Google Patents

Info

Publication number
JP2021518348A5
JP2021518348A5 JP2020549046A JP2020549046A JP2021518348A5 JP 2021518348 A5 JP2021518348 A5 JP 2021518348A5 JP 2020549046 A JP2020549046 A JP 2020549046A JP 2020549046 A JP2020549046 A JP 2020549046A JP 2021518348 A5 JP2021518348 A5 JP 2021518348A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
chain variable
variable domain
Prior art date
Application number
JP2020549046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518348A (ja
JPWO2019180576A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/052166 external-priority patent/WO2019180576A1/en
Publication of JP2021518348A publication Critical patent/JP2021518348A/ja
Publication of JPWO2019180576A5 publication Critical patent/JPWO2019180576A5/ja
Publication of JP2021518348A5 publication Critical patent/JP2021518348A5/ja
Priority to JP2023172559A priority Critical patent/JP2024012300A/ja
Pending legal-status Critical Current

Links

JP2020549046A 2018-03-20 2019-03-18 医薬併用 Pending JP2021518348A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023172559A JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645754P 2018-03-20 2018-03-20
US62/645,754 2018-03-20
PCT/IB2019/052166 WO2019180576A1 (en) 2018-03-20 2019-03-18 Pharmaceutical combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172559A Division JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Publications (3)

Publication Number Publication Date
JP2021518348A JP2021518348A (ja) 2021-08-02
JPWO2019180576A5 JPWO2019180576A5 (https=) 2022-03-28
JP2021518348A5 true JP2021518348A5 (https=) 2022-03-28

Family

ID=66251830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020549046A Pending JP2021518348A (ja) 2018-03-20 2019-03-18 医薬併用
JP2023172559A Pending JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023172559A Pending JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Country Status (14)

Country Link
US (1) US20210363254A1 (https=)
EP (1) EP3768717A1 (https=)
JP (2) JP2021518348A (https=)
KR (1) KR20200134253A (https=)
CN (1) CN111868088A (https=)
AU (2) AU2019240200B2 (https=)
BR (1) BR112020018755A2 (https=)
CA (1) CA3092307A1 (https=)
CL (1) CL2020002379A1 (https=)
IL (1) IL277334A (https=)
MX (1) MX2020009614A (https=)
RU (1) RU2020133811A (https=)
TW (1) TWI791794B (https=)
WO (1) WO2019180576A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016100882A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US20180222982A1 (en) * 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
RU2020142739A (ru) * 2015-08-28 2021-01-15 Новартис Аг Ингибиторы mdm2 и их комбинации
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
HK1254635A1 (zh) * 2015-12-17 2019-07-26 Novartis Ag C-met抑制剂与pd-1抗体分子的组合及其用途
EP4368200A3 (en) * 2017-04-05 2024-07-17 Boehringer Ingelheim International GmbH Anticancer combination therapy

Similar Documents

Publication Publication Date Title
JP2019517549A5 (https=)
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2019503349A5 (https=)
JP2020508317A5 (https=)
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
JP2021521205A5 (https=)
JP2014132009A5 (https=)
JP2012500180A5 (https=)
JP2021528423A5 (https=)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
MX2015001627A (es) Terapia de combinacion para el tratamiento de glioblastoma.
JP2015500822A5 (https=)
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2021518348A5 (https=)
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
RU2020133811A (ru) Фармацевтические комбинации
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
JPWO2019180576A5 (https=)
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
JP2020507569A5 (https=)
CN113491769A (zh) 药物联合
JP2021508699A (ja) トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用